Since pancreatic cancer has a very poor prognosis due to late occurrence of symptoms and therefore late detection, surveillance for pancreatic cancer is currently offered to p16-Leiden germline mutation carriers in a research setting to investigate whether pancreatic cancer, or, even more preferable, high-grade precursor lesions can be detected earlier in a potentially still curable stage [4]. The gene discussed is CDKN2A; the disease is pancreatic neoplasm.